Comparison of Colon Cleansing Quality Between the Setting of Colon Cleansing Room and the Standard Colon Preparation in a Community Base Setting -- a Prospective Randomized Controlled Trial

July 29, 2014 updated by: National Taiwan University Hospital
The quality of colon preparation plays a crucial role in colon cancer prevention, especially for right side colon. So far, colon cleansing is still not adequate in up to 10-30% colonoscopies and leads to increase risk of missed neoplasm.Recent literature on colonoscopy preparation revealed the dosage, timing and dietary restriction could influence colon preparation quality. Previous study demonstrated colon cleansing on the day of colonoscopy had better cleansing quality. However, the ideal colon preparation is not yet determined. the investigators herein consider the in-hospital setting of colon cleansing room can ensure better colon cleansing timing, colon preparation evaluation reliability and patient's compliance of colon cleansing. Therefore, the investigators design a prospective randomized controlled trial to compare cleansing quality between the setting of colon cleansing room and the standard colon preparation.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The investigators prospectively enroll 130 adults that receive colonoscopy examination from Jan 1, 2014 to June 30, 2014. Written Inform consents are achieved before colonoscopy. All patients are randomly assigned to group A and group B. The group A is named as "the setting of colon cleansing room group". The group B is named as " the standard colon preparation group". The randomization was done by a study nurse who is well trained about the teaching course of bowel cleansing level evaluation, low residual diet education and preparation method. Demographic data is collected through questionnaire before colonoscopy. Diet restriction for two days with lower residual diet is well educated through a detail checklist. All patients receive a brief counselling session. The investigators outline the colon preparation instructions. The investigators also explain the rationale for colon preparation with a complete checklist and the picture of colon cleansing assessment. All patients in group B initiate the standard colon preparation with PEG-ELS made from two sachets of PEG (Klean-PrepTM, Norgine Ltd. Harefield, Middlesex, United Kingdom) dissolved in 2 L of water at 8:00 AM on the day of colonoscopy. All patients in group A drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy. The time interval in both group between colon preparation and colonoscopy is 3 to 5 hours. All colonoscopies are performed by two endoscopists in Jin-Shan Branch Hospital with an Olympus CF-260AL colonoscope (Olympus Optical Co. Ltd., Tokyo, Japan). All endoscopists were trained at National Taiwan University Hospital with at least eight hundred colonoscopy experience. The endoscopist follow the standard protocol to insert, withdraw and observation. Intramuscular injection of hyoscine butylbromide is done as antispasmodic if there is no contraindication. Complete colonoscopy is defined as reaching and taking a picture of the cecum. Endoscopists take pictures at every anatomical portion of colon including cecum, ascending colon, transverse colon, descending colon, sigmoid colon and rectum before and after fecal material is washed out. Theendoscopist also record all of the colonoscopy examination as video files. All colonoscopists are asked to take at least thirty pictures during whole colonoscopy examination. Colon cleansing quality is scored by Boston Bowel Preparation Quality Scale. The scale is applied to each colon segment including right colon (R), middle colon (T) and the rectosigmoid colon(L). The score is calculated by adding the 0 to 3 ratings for each colon section. Electronic files of endoscopic pictures without lesion presentation and edited videos were reviewed by all endoscopist. All the detected adenomas during both study group are recorded and stored as electronic files and video including location, size, morphology and endoscopic diagnosis. The primary endpoint of study is to compare the Boston Bowel Preparation Quality Scale between the two study group. The secondary endpoint is to compare the average number of adenoma detection between the two study group. Sample size is estimated by the average number of adenoma detected (1.0 lesions per subject in standard preparation group, SD 1.0 and 1.5 lesions per subject in hospital preparation group, SD 1.0) according to a previous study in National Taiwan University Hospital and the pilot study in National Taiwan University Hospital , Jin Shan Branch , more than 80% power by enrolling 65 subjects in each group are achieved ( t test, α error of 0.05).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
130

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • New Taipei City, Taiwan, 208
        • National Taiwan University Hospital, Jin Shan branch

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients who are indicated and willing to recieve colonoscopic examination

Exclusion Criteria:

  • 1. previous history of colorectal surgery
  • 2. toxic colitis
  • 3. pregnancy woman
  • 4. acute myocardial infarction or unstable angina.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: colon cleansing room group
All patients in colon cleansing room group drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
Procedure: colonoscopic examination in colon cleansing room
All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
Placebo Comparator: standard colon preparation group
All patients in the standard colon preparation groupinitiate the standard colon preparation with PEG-ELS made from two sachets of PEG (Klean-PrepTM, Norgine Ltd. Harefield, Middlesex, United Kingdom) dissolved in 2 L of water at 8:00 AM on the day of colonoscopy.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Boston Bowel Preparation Quality Scale
Time Frame: eight months
The scale is applied to each colon segment including right colon (R), middle colon (T) and the rectosigmoid colon(L). The score is calculated by adding the 0 to 3 ratings for each colon section.
eight months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
the average detected adenoma number
Time Frame: eight months
eight months

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Number of Adverse Events
Time Frame: eight months
Side effect of PEG-ELS will be monitored.
eight months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
National Taiwan University Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: tsai kun feng, master, National Taiwan University Hospital Jin-Shan branch

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2014

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2014

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2014

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 21, 2014

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 23, 2014

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 27, 2014

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 31, 2014

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 29, 2014

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2014

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 201310073RINA

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings